ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $706.66M |
| EBITDA | $98.39M |
| Operating Margin | 12.30% |
| Return on Equity | 35.70% |
| Return on Assets | 3.64% |
| Revenue/Share (TTM) | $6.69 |
| Book Value | $7.59 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 2.89 |
| EV/Revenue | 3.07 |
| EV/EBITDA | 35.53 |
| Quarterly Earnings Growth (YoY) | 13.30% |
| Quarterly Revenue Growth (YoY) | 16.40% |
| Shares Outstanding | $171.24M |
| Float | $128.35M |
| % Insiders | 0.33% |
| % Institutions | 99.83% |
Volatility is currently contracting
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
Options bears are circling three stocks today, with Aemetis Inc (NASDAQ:AMTX), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), and Resideo Technologies Inc (NYSE:REZI) all seeing puts handily outpace calls.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
